Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients
Metrics: PDF 994 views | HTML 1214 views | ?
Yuhan Wang1, Yingying Han1, Qiang Weng1, Zhengrong Yuan1
1College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People’s Republic of China
Zhengrong Yuan, email: firstname.lastname@example.org
Keywords: XPG, rs2296147, cancer, clinical outcomes, meta-analysis
Received: May 24, 2016 Accepted: August 11, 2016 Published: August 29, 2016
The Xeroderma pigmentosum complementation group G (XPG) rs2296147T>C polymorphism is suspected to associate with the clinical outcomes of cancer patients. However, the results are inconsistent. This meta-analysis aimed to evaluate the reliable predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. A total of 11 eligible studies were enrolled in this meta-analysis. Our results indicated that the cancer patients with TT and CT genotypes were significantly associated with better respond rates when compared with the CC genotype (TT versus (vs.) CC: odds ratio (OR) = 2.05, 95% confidence intervals (CIs), 1.32-3.20, P = 0.002; TT+CT vs. CC: OR= 1.57, 95% CI, 1.14-2.17, P = 0.005). The TT genotype and/or T allele might be associated with higher survival time for cancer patients than the CC genotype and/or C allele. The cumulative meta-analyses showed an apparent beneficial objective response of TT genotype on cancer patients. In conclusion, this meta-analysis suggests that the XPG rs2296147T>C polymorphism is associated with the clinical outcomes of cancer patients. The XPG rs2296147T>C polymorphism might be a predictive factor of prognosis in cancers patients and contribute to individual treatment in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.